Intelligence Report · ~15 min read
ENT · Surgical Intervention Therapeutic Area Assessment
1 signals · 0 insights · 5 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Low Confidence · 58%
Evidence
6 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for ENT · Surgical Intervention integrates 1 signals, 0 executive insights, and 5 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 19, 2026
Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children
A multi-center feasibility study is underway to assess the safety and efficacy of the IRE System for treating adenotonsillar hypertrophy in children.
View detail - regulatoryJul 19, 2026
[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted
PMDA regulatory document relevant to this signal.
View detail - regulatoryJul 19, 2026
Pulmonary Valve Catheter Delivery System Recall: Medtronic Removes Harmony Delivery Catheter System (DCS)
The distal tip in certain lots of the Medtronic Harmony Delivery Catheter System (DCS) may detach which can require endovascular retrieval or surgical intervention.
View detail - regulatoryJul 19, 2026
FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)
Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.
View detail - regulatoryJul 19, 2026
FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Insight synthesis pending additional signal clustering in this therapeutic area. 5 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted
83%PMDA regulatory document relevant to this signal.
Source: PMDA
View evidencePulmonary Valve Catheter Delivery System Recall: Medtronic Removes Harmony Delivery Catheter System (DCS)
72%The distal tip in certain lots of the Medtronic Harmony Delivery Catheter System (DCS) may detach which can require endovascular retrieval or surgical intervention.
Source: FDA
View evidenceFDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)
72%Application NDA022155. Sponsor: KENVUE BRANDS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CETIRIZINE HYDROCHLORIDE.
Source: FDA
View evidenceFDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
72%Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.
Source: FDA
View evidenceQuantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials
72%Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as adenotonsillar hypertrophy treatment protocols.
Source: FDA
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.